+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT compared to a placebo in treating psychosis linked to Alzheimers Disease. This Phase 3 outpatient study lasts 38 weeks and aims to prevent relapse of psychosis symptoms in affected adults aged 55 to 90. The trial also looks at how long participants stay on treatment without relapse or stopping for any reason, along with monitoring safety and tolerability. Participants are randomly assigned to receive either KarXT capsules in varying doses or placebo capsules. The treatment is administered three times a day during the study period. This double-blind trial ensures neither participants nor researchers know which treatment is given. The study is conducted at multiple centers and includes a placebo control to compare outcomes. Throughout the 38 weeks, participants will attend regular visits for assessments including cognitive tests like the Mini-Mental State Examination, evaluations of psychosis severity, caregiver-reported measures, and safety monitoring such as laboratory tests, vital signs, and adverse event tracking. Researchers will measure the time to relapse and treatment discontinuation, along with side effects and other health indicators. The study is sponsored by Karuna Therapeutics, a Bristol Myers Squibb company.

Age: 55Years - 90YearsAll GendersPhase 3
129 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the combination of KarXT and KarX-EC for cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3, randomized, double-blind, placebo-controlled study aims to understand how these treatments impact cognitive function and overall condition in this patient group. Participants will be randomly assigned to receive either KarXT plus KarX-EC or a placebo, with specified doses given on specific days. The treatment period lasts 24 weeks, during which participants will be monitored closely to assess changes in cognition and daily functioning. Throughout the 24 weeks, participants will undergo evaluations including cognitive tests like the Alzheimers Disease Assessment Scale-Cognitive Subscale 11 and the Clinicians Interview-Based Impression plus Caregiver Input. Researchers will also track safety through monitoring adverse events, vital signs, lab tests, and other clinical assessments to understand the treatments impact and safety profile.

Age: 60Years - 85YearsAll GendersPhase 3
119 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
M

Actively Recruiting

Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.

Age: 55Years - 95YearsAll GendersPhase 2Phase 3
154 locations
E

Actively Recruiting

Researchers are conducting a national, prospective, multicenter observational pilot project in the Czech Republic to screen for Chronic Thromboembolic Pulmonary Hypertension CTEPH in patients who have experienced Acute Pulmonary Embolism APE. The study aims to develop and evaluate a standardized early detection procedure to improve patient outcomes and ensure cost-effective healthcare. This project involves multiple centers and targets patients after APE to facilitate timely diagnosis and treatment referral. Participants who have had APE will undergo a standardized screening protocol for early identification of CTEPH. If there is a risk identified during screening, patients will be referred promptly to specialized pulmonary hypertension centers for further management. This process includes implementing and testing a uniform screening algorithm and ensuring efficient patient flow from cardiologists to specialized treatment centers. During the study, participants will be assessed using this screening process within six months of enrollment. Key outcomes include the positive predictive value of the initial examination, rates of CTEPH detection, and the proportion of suspected cases attending follow-up at specialized centers. The study will monitor these factors to validate the screening protocols effectiveness and impact on patient care, with follow-up continuing up to six months after enrollment.

Age: 18Years +All Genders
10 locations
L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations
D

Actively Recruiting

Researchers are conducting a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This study aims to understand how ACP-204 affects psychosis symptoms in participants aged 55 to under 85 years. It compares two doses of ACP-204 against a placebo over a six-week period. Participants are assigned to one of three groups receiving 30 mg of ACP-204 once daily, 60 mg of ACP-204 once daily, or a placebo once daily. The medication is provided as a capsule taken orally. The study lasts six weeks, during which participants take their assigned treatment daily while remaining unaware of their group assignment. Throughout the trial, participants will be monitored regularly to assess changes in their psychosis symptoms using the SAPS-LBDP total score at week 6. Safety and tolerability will also be evaluated. The study includes screening for eligibility, regular visits during treatment, and assessments to track symptom changes and any side effects over the six-week treatment period.

Age: 55Years - 84YearsAll GendersPhase 2
62 locations
W

Actively Recruiting

Researchers are conducting a 52-week, open-label extension study to evaluate ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This Phase 3 trial aims to assess long-term treatment effects and safety in participants who have previously completed an antecedent ACP-204 study. The study is sponsored by ACADIA Pharmaceuticals Inc. and focuses on adults aged 55 to 84 years. Participants will receive ACP-204 capsules taken orally once daily, starting at 30 mg. The dose may be adjusted during the trial, allowing for increases to 60 mg or reductions back to 30 mg depending on treatment response. The study design includes a single treatment group with no placebo or comparison groups, and treatment is provided openly without masking. Throughout the 52 weeks, participants and their study partners or caregivers will attend all study visits and complete assessments under supervision. Researchers will monitor for treatment-emergent adverse events as the primary outcome. Participants must be able to provide informed consent or assent with consent from a legally authorized representative. Safety and efficacy evaluations will be conducted regularly to ensure participant well-being during the study period.

Age: 55Years - 84YearsAll GendersPhase 3
36 locations